Incyte (INCY) Research & Development (2010 - 2026)
Incyte (INCY) reported Research & Development of $515.9 million for Q1 2026, up 17.98% on a YoY basis from $437.3 million in Q1 2025, and up 2916.98% quarter-over-quarter from $17.1 million in Q4 2025.
Incyte (INCY) Research & Development (2010 - 2026) Analysis & Trends
Incyte has reported Research & Development for 17 years, with the latest figure at $515.9 million in Q1 2026.
- For the quarter ending Q1 2026, Research & Development rose 17.98% year-over-year to $515.9 million; the trailing twelve-month figure through Mar 2026 stood at $1.5 billion (down 41.32% YoY), and the FY2025 full-year result was $2.1 billion, down 21.36% from the prior year.
- Research & Development for Q1 2026 stood at $515.9 million, up from $17.1 million in the prior quarter.
- The five-year high for Research & Development was $1.1 billion in Q2 2024, with the low at $17.1 million in Q4 2025.
- Historically, Research & Development has averaged $458.4 million across 5 years, with a median of $437.3 million in 2025.
- Annual changes were most pronounced in 2024 — Research & Development jumped 184.06% — and 2025, when it plunged 96.33%.
- Incyte's Research & Development stood at $501.4 million in 2022, then dropped by 11.34% to $444.5 million in 2023, then grew by 4.85% to $466.0 million in 2024, then sank by 96.33% to $17.1 million in 2025, then jumped by 2916.98% to $515.9 million in 2026.
- The last three Research & Development figures came in at $515.9 million (Q1 2026), $17.1 million (Q4 2025), and $506.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 4.32 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 15.66 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 626,092.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -101.30 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -2.30 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 1.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 357,444.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 961.60 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -58.00 Mn |
| 10 | Incyte | 19.62 Bn | 15.60 Bn | 1.17 Bn | 515.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 515.90 Mn |
| Dec 31, 2025 | 17.10 Mn |
| Sep 30, 2025 | 506.58 Mn |
| Jun 30, 2025 | 494.92 Mn |
| Mar 31, 2025 | 437.28 Mn |
| Dec 31, 2024 | 466.03 Mn |
| Sep 30, 2024 | 573.17 Mn |
| Jun 30, 2024 | 1.14 Bn |
| Mar 31, 2024 | 429.26 Mn |
| Dec 31, 2023 | 444.49 Mn |
| Sep 30, 2023 | 375.71 Mn |
| Jun 30, 2023 | 400.75 Mn |
| Mar 31, 2023 | 406.64 Mn |
| Dec 31, 2022 | 501.36 Mn |
| Sep 30, 2022 | 384.01 Mn |
| Jun 30, 2022 | 347.20 Mn |
| Mar 31, 2022 | 353.37 Mn |
| Dec 31, 2021 | 472.83 Mn |
| Sep 30, 2021 | 334.95 Mn |
| Jun 30, 2021 | 343.51 Mn |